FGFR2-RUNX2激活:与瘤进展相关的光线乳腺癌中尚未探索的治疗途径

相关实验视频

Updated: Jun 4, 2025

10:56

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis

Published on: August 1, 2019

8.1K

María S Rodriguez¹, Yamil D Mahmoud^1,2, Silvia Vanzulli¹

¹Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina.

International journal of cancer

|December 28, 2024

概括

RUNX2驱动着光线乳腺癌 (BrCa) 的进展和转移,即使FGFR2被静止. 准RUNX2可能为攻击性光BrCa提供新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

发光性乳腺癌 (BrCa) 的进展是患者生存的重大挑战.
RUNX2与三阴BrCa攻击性有关,但其在光瘤中的作用尚不清楚.
之前的研究表明,活跃的FGFR2 (FGFR2-CA) 增加了瘤生长,而RUNX2在荷尔蒙独立的小鼠乳腺癌中升高.

研究的目的:

研究FGFR2和RUNX2在人类BrCa进展和治疗反应中的相互作用.
为了确定RUNX2在光线乳腺癌攻击性中的作用.
评估RUNX2作为潜在的治疗标和预后生物标志物.

主要方法:

研究了FGFR2活性和RUNX2表达对BrCa细胞增殖和转移的影响.
使用细胞沉默和过度表达技术用于FGFR2和RUNX2.2.
在体外使用CBFβ-RUNX复合抑制剂AI-14-91.
在患者样本中分析了核RUNX2表达,并进行了转录基因分析.

主要成果:

增加的FGFR2活性导致更高的RUNX2表达,扩散和转移;沉默FGFR2扭转了这些影响.
在FGFR2抑制细胞中RUNX2过度表达恢复了侵略性的表型.
过度表达RUNX2的瘤对内分泌和FGFR抑制剂治疗具有抗性.
核RUNX2表达与光线BrCa患者的瘤复发相关.
高的RUNX2活动得分与更糟糕的无进展间隔有关.

结论:

在调节瘤攻击性方面,FGFR2和RUNX2之间存在复杂的相互作用.
RUNX2在光线BrCa进展中发挥着重要作用.
RUNX2是一种有前途的治疗标和预后生物标志物,用于光线BrCa.

关键词:

在FGFR的基础上.在RUNX2中使用RUNX2.乳腺癌乳腺癌乳腺癌内分泌耐药性的内分泌抵抗.内分泌疗法是一种内分泌疗法.

相关概念视频

02:38

Mitogens and the Cell Cycle

6.4K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

6.4K

01:16

TGF - β Signaling Pathway

7.2K

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

7.2K

03:03

mTOR Signaling and Cancer Progression

3.7K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

3.7K

01:20

The Retinoblastoma Gene

4.0K

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

4.0K

02:54

Canonical Wnt Signaling Pathway

8.7K

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...

8.7K

02:57

Targeted Cancer Therapies

7.4K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...